QQ客服 官方微博 反馈留言

	Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study
	Xu, Lisheng; Qi, Qian; Zhang, Yan; Cui, Jiadong; Liu, Ruijuan; Li, Yu
刊名	LUNG CANCER
	2019
卷号	133页码:23-31
关键词	EGFR Lung adenocarcinoma Icotinib Chemotherapy Combination therapy First-line
DOI	10.1016/j.lungcan.2019.05.008
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4545818
专题	山东大学
作者单位	Shandong Univ, Qilu Hosp, Dept Resp Med, 107 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
推荐引用方式 GB/T 7714	Xu, Lisheng,Qi, Qian,Zhang, Yan,et al. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study[J]. LUNG CANCER,2019,133:23-31.
APA	Xu, Lisheng,Qi, Qian,Zhang, Yan,Cui, Jiadong,Liu, Ruijuan,&Li, Yu.(2019).Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.LUNG CANCER,133,23-31.
MLA	Xu, Lisheng,et al."Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study".LUNG CANCER 133(2019):23-31.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。